News

The expansion is anticipated to be fully operational end of the first quarter of 2015. The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use

The payment settles charges brought by 45 state attorneys general, while California’s portion of the settlement is around $7.1m. The settlement prohibits the UK drug-maker from providing incentive

The submitted pre-IND package provides the US FDA with information on the company’s REV-002, as well as a clinical trial plan for a proposed US clinical trial. The

The final closing of the transaction is expected to take place on or before 07 July 2014. The acquisition is a significant milestone for GelStat and is expected

Recently, the US Adopted Names (USAN) Council has adopted necuparanib as the unique non-proprietary name for M402. Necuparanib, a heparan sulfate mimetic, is a novel oncology drug candidate

The patent is expected to be issued during 2014 and will have a 2029 expiry date. RHB-104 is a proprietary antibiotic combination oral capsule formulation for the treatment

The claims of this National Stage Application cover delivery technology based on Marina’s proprietary SMARTICLES amphoteric liposomes and directly support the clinical programs of the company’s licensees ProNAi

In the trial, AD04 showed clinical and biomarker effects consistent with disease modification in Alzheimer patients. Following treatment with AD04, effects consistent with disease modification were achieved for

After a careful and prolonged pre start-up process, this highly qualified group of liver centers has already evolved into a formal alliance – LALREAN. Although the Scientific Leaders